Markets.com Logo

TBIO

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    0.0217$
  • Previous Close
    0.0217$
  • 52 Week Change
    5.07$
  • Day Range
    0.00$
  • 52 Week High/Low
    0.012$ - 5.08$
  • Dividend Per Share
    --
  • Market cap
    39 068$
  • EPS
    -4.0938
  • Beta
    2.783
  • Volume
    --

About

TBIO.US represents the common stock of Translate Bio, Inc., a company formerly focused on developing messenger RNA (mRNA) therapeutics. Translate Bio was acquired by Sanofi in August 2021. Therefore, TBIO.US is no longer actively traded on the stock market, and its price history reflects its value prior to the acquisition. Prior to its acquisition, Translate Bio focused on developing mRNA therapeutics for various diseases, including cystic fibrosis and liver diseases.
NBIS Stock Outlook for 2026: What will be the future of Nebius Group?

NBIS Stock Outlook for 2026: What will be the future of Nebius Group?

Frances Wang|--
Commodity market today: Will Gold (XAU/USD) and Silver (XAG) hit new highs?

Commodity market today: Will Gold (XAU/USD) and Silver (XAG) hit new highs?

Frances Wang|--
RGTI stock crashed 7% today: what’s happening with Rigetti Computing?

RGTI stock crashed 7% today: what’s happening with Rigetti Computing?

Frances Wang|--
Gold price analysis: XAU/USD price today, how high will gold go in 2026?

Gold price analysis: XAU/USD price today, how high will gold go in 2026?

Frances Wang|--
Technology stock to watch in 2026: What is the new NVDA stock price target?

Technology stock to watch in 2026: What is the new NVDA stock price target?

Frances Wang|--
BMNR stock up 9% today: what’s going on with BitMine Immersion Technologies?

BMNR stock up 9% today: what’s going on with BitMine Immersion Technologies?

Frances Wang|--
Solana (SOL) price analysis: What will SOL/USD be worth in 2026?

Solana (SOL) price analysis: What will SOL/USD be worth in 2026?

Frances Wang|--

Factors

Clinical Trial Results: Positive data boosts investor confidence, driving up demand and stock price. Negative results or trial failures often lead to significant price drops.

Regulatory Approvals: FDA approval of TBIO's drugs or therapies is a major catalyst, increasing revenue potential and stock valuation. Rejections or delays can negatively impact the stock.

Market Sentiment: General market trends, investor optimism or pessimism, and the overall health of the biotechnology sector influence TBIO's stock price.

Competition: The presence of competing products or companies in the same therapeutic area can affect TBIO's market share and stock performance.

Financial Performance: Revenue, earnings, and profitability reports impact investor perception of TBIO's value and future growth prospects.

Partnerships and Acquisitions: Collaborations with other companies or potential acquisition targets can lead to increased stock value.

People Also Watch

Latest news

ESMA Expansion Sparks Crypto, Fintech Slowdown Concerns in EU

Noah Lee|--

Bitcoin's 'Santa' Rally: Fed Rate Decision and 2026 Outlook

Noah Lee|--

Western Union Unveils Stable Card, Stablecoin Strategy to Combat Inflation

Liam James|--

Latest Education Articles

A Complete Guide to Cryptos: How to Invest in Crypto as A BEGINNER In 2026?

A Complete Guide to Cryptos: How to Invest in Crypto as A BEGINNER In 2026?

Ghko B|--
Contracts for Difference explained: What is CFD trading, how do CFDs work?

Contracts for Difference explained: What is CFD trading, how do CFDs work?

Ghko B|--
Financial market for beginners: How financial markets work, how to invest?

Financial market for beginners: How financial markets work, how to invest?

Ghko B|--